Amneal Pharmaceuticals Inc is committed to delivering quality generic pharmaceutical products. Their corporate philosophy revolves around providing affordable, accessible, and innovative healthcare solutions. With a focus on research and development, they strive to improve patient lives and enhance overall well-being. By offering a diverse portfolio of high-quality generic medications, Amneal Pharmaceuticals Inc aims to make healthcare more accessible and contribute to the overall welfare of society. They prioritize excellence, accountability, and integrity, all while aiming to deliver sustainable value to patients, healthcare providers, and other stakeholders.

Amneal Pharmaceuticals Inc is primarily present in the United States.

Amneal Pharmaceuticals Inc has achieved several significant milestones throughout its history. The company has successfully expanded its product portfolio, offering a wide range of generic pharmaceuticals, specialty drugs, and over-the-counter products. Additionally, Amneal Pharmaceuticals Inc has made strategic acquisitions and partnerships to strengthen its global presence and enhance its research and development capabilities. The company has also received multiple approvals from regulatory authorities for its Abbreviated New Drug Applications (ANDAs) and has launched various generic medications in the market. Overall, Amneal Pharmaceuticals Inc has demonstrated continuous growth and innovation, positioning itself as a leading player in the pharmaceutical industry.

Amneal Pharmaceuticals Inc is a prominent pharmaceutical company with a rich history and background. Founded in 2002, the company has grown rapidly to become a leading provider of high-quality generic and specialty pharmaceutical products. Amneal focuses on developing, manufacturing, and distributing a diverse range of innovative and affordable medications to improve patients' lives. With a strong commitment to quality, the company has established a robust portfolio of FDA-approved products and consistently achieves high safety and efficacy standards. Amneal Pharmaceuticals Inc has also expanded globally, operating in multiple countries to serve a wider patient population.

The main competitors of Amneal Pharmaceuticals Inc in the market include major pharmaceutical companies such as Teva Pharmaceutical Industries Ltd, Mylan N.V, and Endo International plc.

Amneal Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Amneal Pharmaceuticals Inc is focused on developing, manufacturing, and distributing high-quality generic and specialty pharmaceutical products. Amneal aims to provide affordable and accessible medications to patients worldwide, while adhering to stringent quality standards. The company operates through its robust supply chain, leveraging its extensive manufacturing capabilities and scientific expertise to produce a diverse portfolio of pharmaceutical products. Amneal Pharmaceuticals Inc is dedicated to continuously improving patient outcomes by delivering innovative and cost-effective solutions across therapeutic areas such as cardiovascular, central nervous system, and infectious diseases, among others.

Amneal Pharmaceuticals KGV ir 6,43.

Amneal Pharmaceuticals KUV ir 0,45.

AlleAktien kvalitātes vērtējums Amneal Pharmaceuticals ir 5/10.

gaidāmā Amneal Pharmaceuticals apgrozījums ir 2,61 miljardi USD.

gaidāmā Amneal Pharmaceuticals peļņa ir 182,60 milj. USD.

Amneal Pharmaceuticals Inc is an internationally operating company in the pharmaceutical industry that specializes in the development, manufacturing, and marketing of generics and innovative products. The business model is based on a diversified production and sales strategy, which enables the company to be successful in different markets and product categories. The company is active in several segments, including generics, innovative products, specialty pharma, and biosimilars. In the generics segment, the company offers a variety of high-quality generic drugs for different therapeutic areas, which have the same quality and efficacy as the original products. The innovative products include innovative drugs for rare diseases and specialized therapeutic areas. In the specialty pharma segment, the company offers a wide range of drugs for specialized therapies, which are often intended for patients with severe or rare diseases. The biosimilars segment focuses on the development and marketing of biosimilars for various therapy areas, such as oncology. Amneal Pharmaceuticals Inc also offers over-the-counter drugs, dietary supplements, and cosmetics. The company has successfully launched a variety of products in these categories to meet the consumers' needs for self-care products and a healthy lifestyle. Another important aspect of Amneal Pharmaceuticals Inc's business model is the targeted expansion of the company through strategic acquisitions and partnerships. In the past, the company has already made some successful acquisitions of competitors to expand its product portfolio and increase sales. The company places particular emphasis on quality assurance and sustainable business practices. Amneal Pharmaceuticals Inc pursues a comprehensive quality management system that meets the highest requirements and standards. Sustainability also plays an important role in the company's business model. Amneal Pharmaceuticals Inc aims to develop environmentally friendly processes and products to contribute to the protection of the environment. In summary, the business model of Amneal Pharmaceuticals Inc is based on a broad range of products, diversified sales strategies, and targeted expansion and acquisition strategies. The consistent adherence to the highest quality and sustainability standards, as well as the focus on specialty therapies and innovative products, have made the company an important player in the pharmaceutical industry. Only the first and the last sentence are to be written in the answer field.

Amneal Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Amneal Pharmaceuticals vai uzņēmums nedod dividendes.

Amneal Pharmaceuticals ISIN ir US03168L1052.

Amneal Pharmaceuticals WKN ir A2JLMD.

Amneal Pharmaceuticals simbols ir AMRX.

Pēdējo 12 mēnešu laikā Amneal Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Amneal Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Amneal Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Amneal Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Amneal Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Amneal Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Amneal Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 7.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 7.07.2024..

Pēdējās dividendes izmaksa notika 7.07.2024..

Gadā 2023, Amneal Pharmaceuticals izmaksāja 0 USD dividendes.

Amneal Pharmaceuticals dividendes tiek izmaksātas USD.